Device Heart Failure

Reds System

Payments companies reported to CMS as associated with Reds System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$231Kassociated payments (2023-2025)
58clinicians with associated payments
2companies reporting

By year

2023 $88K
2024 $73K
2025 $70K

Payments reported as associated with Reds System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Advanced Heart Failure and Transplant Cardiology $229K
Cardiovascular Disease $758
Internal Medicine $199
Emergency Medicine $192
Obstetrics & Gynecology $62.73
Interventional Cardiology $48.15

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Reds System

These are the largest totals companies reported as associated with Reds System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Daniel Bensimhon Greensboro, NC Advanced Heart Failure and Transplant Cardiology $123,636.15
William Abraham Columbus, OH Advanced Heart Failure and Transplant Cardiology $105,000.00
Sean Pinney New York, NY Advanced Heart Failure and Transplant Cardiology $186.82
Jeffrey Oyler Atlanta, GA Emergency Medicine $160.05
Robert Cole Atlanta, GA Advanced Heart Failure and Transplant Cardiology $131.70
Wesley Tyree Scottsdale, AZ Cardiovascular Disease $112.21
Gregory Heumann North Vernon, IN Internal Medicine $105.89
Michael Shen Weston, FL Cardiovascular Disease $81.50
Keesag Baron Springfield, MO Cardiovascular Disease $79.90
Sateesh Kesari Cincinnati, OH Advanced Heart Failure and Transplant Cardiology $69.55

Prescribed Reds System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.